An Update on Non Metastatic Castration-Resistant Prostate Cancer

Neal Shore | March 04, 2019

Androgen deprivation therapy (ADT) is the backbone of therapy for advanced prostate cancer patients who have failed primary interventional therapy.  Most of these patients will develop, through a potential multitude of resistance mechanisms, neoplastic cellular progression, and proliferation which subsequently leads to PSA relapse.2 Castration-resistant prostate cancer (CRPC), a rising PSA with castrate levels of testosterone alongside no radiographic imaging findings with conventional imaging (CT/Bone scans) are designated as non-metastatic (nmCRPC), or sometimes as M0CRPC.


Neal Shore, MD, FACS

Neal Shore, MD, is the Medical Director of the Carolina Urologic Research Center. He practices with Atlantic Urology Clinics in Myrtle Beach, South Carolina. He serves on several industry advisory boards as well as academic and advocacy networks: including the Society Urologic Oncology Clinical Trials Consortium, Bladder Cancer Advocacy Network, and the Large Urology Group Practice Association. Dr. Shore is the editor-in-chief of UroToday’s print publication, Everyday Urology- Oncology Insights.

Conference Coverage
Recent data from conferences worldwide

EAU 2019 Prostate Cancer

ASCO GU 2019 Prostate Cancer

CUOS 2019 Prostate Cancer

SUO 2018 Prostate Cancer

AUA 2018 Northeastern Section

CUA 2018 Prostate Cancer

ASCO 2018 Prostate Cancer

AUA 2018 Prostate Cancer

ASCO GU 2018 Prostate Cancer

An extensive resource of papers on urological diseases and conditions
Clinical Trials
Searchable database of currently enrolling clinical trials

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.